Cardio firms including AstraZeneca and Novartis to showcase heart drug data at ESC 2026

At the European Society of Cardiology's annual meeting in 2026, several pharmaceutical companies will present cardiovascular data.

The lineup includes AstraZeneca, Ionis, Cytokinetics, Novartis and CRISPR Therapeutics, each looking to demonstrate the potential of their heart-focused drug programs.

These sessions are intended to give the companies a sense of market interest and to inform investors about the outlook for their cardiovascular pipelines.

Stakeholders will be watching the data closely as it could shape future development and commercial strategies in the cardio space.